Enterprise record
Alpha ID: alpha:company:46ce4d2c-369f-41dd-a9c6-5d1975299a04Version: public-1As of: unavailable
10 published Claims2 sources
Key Claims
Board and committees
Evidence, history and coverage
Additional published Claims
Published evidence records
2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Alpha canonical company public projection
canonical identity · Source published: Date unavailable · Retrieved: Sep 30, 2026
Supports 3 claims
- Legal Name: Atrium Therapeutics, Inc. · Claim reviewed: Sep 30, 2026
- Entity Status: Public listing published · Claim reviewed: Sep 30, 2026
- Published Fact: US · Claim reviewed: Sep 30, 2026
Issuer IR atrium-therapeutics-inc
issuer ir · Source published: Sep 14, 2026 · Retrieved: Sep 14, 2026
Supports 7 claims
- Leadership Role: Sarah Boyce: Chair · Claim reviewed: Sep 30, 2026
- Leadership Role: Carsten Boess: Director · Claim reviewed: Sep 30, 2026
- Leadership Role: Kathleen Gallagher: Chief Executive Officer and Director · Claim reviewed: Sep 30, 2026
- Leadership Role: Simona Skerjanec: Director · Claim reviewed: Sep 30, 2026
- Leadership Role: Troy Wilson: Director · Claim reviewed: Sep 30, 2026
- Leadership Role: W. Michael Flanagan: Director · Claim reviewed: Sep 30, 2026
- Leadership Role: Kathleen Gallagher: Chief Executive Officer · Claim reviewed: Sep 30, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-09-30
- Board and committees
- published
- Control and shareholders
- not observed
- Compensation
- not observed
- Auditors, advisors and reporting
- not observed
- Legal
- not observed
- AI governance
- not observed

